Ironwood Pharmaceuticals (IRWD) Operating Margin (2010 - 2026)
Ironwood Pharmaceuticals (IRWD) reported Operating Margin of 68.14% for Q1 2026, up 13889.0% on a YoY basis from N/an in Q1 2025, and up 377.72% sequentially from 14.26% in Q4 2025.
Ironwood Pharmaceuticals (IRWD) Operating Margin (2010 - 2026) Analysis & Trends
Ironwood Pharmaceuticals (IRWD) has 17 years of Operating Margin data on file, last reported at 68.14% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 13889.0% year-over-year to 68.14%; the trailing twelve-month figure through Mar 2026 stood at 55.37% (up 3869.0% YoY), and the FY2025 full-year result was 33.26%, up 676.0% from the prior year.
- Operating Margin grew to 68.14% in Q1 2026, from 14.26% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 68.14% in Q1 2026 to a low of 1008.68% in Q2 2023.
- A 5-year average of 24.11% and a median of 35.19% in 2023 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin slumped 106592 bps in 2023 and jumped 103514 bps in 2024, its largest moves.
- Tracing IRWD's Operating Margin over 5 years: stood at 63.77% in 2022, then slumped by 50 bps to 31.98% in 2023, then rose by 9 bps to 34.78% in 2024, then tumbled by 59 bps to 14.26% in 2025, then surged by 378 bps to 68.14% in 2026.
- Business Quant data shows IRWD's Operating Margin at 68.14% in Q1 2026, 14.26% in Q4 2025, and 61.84% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Ironwood Pharmaceuticals | 619.48 Mn | 399.01 Mn | - | 68.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.14% |
| Dec 31, 2025 | 14.26% |
| Sep 30, 2025 | 61.84% |
| Jun 30, 2025 | 53.17% |
| Mar 31, 2025 | -70.75% |
| Dec 31, 2024 | 34.78% |
| Sep 30, 2024 | 27.99% |
| Jun 30, 2024 | 26.46% |
| Mar 31, 2024 | 14.72% |
| Dec 31, 2023 | 31.98% |
| Sep 30, 2023 | 35.19% |
| Jun 30, 2023 | -1,008.68% |
| Mar 31, 2023 | 57.75% |
| Dec 31, 2022 | 63.77% |
| Sep 30, 2022 | 63.03% |
| Jun 30, 2022 | 57.24% |
| Mar 31, 2022 | 59.31% |
| Dec 31, 2021 | 48.32% |
| Sep 30, 2021 | 62.82% |
| Jun 30, 2021 | 62.58% |